Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 04, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on December 01, 2006:
- The fund's holdings decreased from 17,429,386 to 17,385,837 ADRs at an average price of $51.55.
- Subsequently, the fund's holdings increased from 17,385,837 to 17,407,470 ADRs at an average price of $53.13.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that Directors Dr. J P Garnier and Dr. M M Slaoui are potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- Transactions were executed on December 01, 2006, and notified on December 04, 2006.
- The transactions involved the GlaxoSmithKline US Retirement Savings Plan, not direct personal trading by directors.
- Two directors (Dr. J P Garnier and Dr. M M Slaoui) have potential interests in the fund's holdings.
- The filing was signed by Victoria Whyte as the Authorised Signatory.